Please login to the form below

Not currently logged in
Email:
Password:

Sarepta Therapeutics

This page shows the latest Sarepta Therapeutics news and features for those working in and with pharma, biotech and healthcare.

Daily Brief: Sarepta deepens gene therapy investment, NICE changes mind on Besponsa, Digital Medicine company Akili raises $13m

Daily Brief: Sarepta deepens gene therapy investment, NICE changes mind on Besponsa, Digital Medicine company Akili raises $13m

Daily Brief: Sarepta deepens gene therapy investment, NICE changes mind on Besponsa, Digital Medicine company Akili raises $13m. ... Sarepta is looking to deepen its presence in gene therapy with a new licensing deal with Lacerta Therapeutics.

Latest news

More from news
Approximately 2 fully matching, plus 10 partially matching documents found.

Latest Intelligence

  • Deal Watch February 2017 Deal Watch February 2017

    Licence. 320. Lonza/ Sanofi. Large scale mammalian cell manufacturing facility for antibody therapeutics. ... Licence. 145. Sarepta Therapeutics/ Gilead Sciences. PRV received when EXONDYS 51 was FDA approved for Duchenne muscular dystrophy.

  • Pharma deals during November 2014 Pharma deals during November 2014

    BioMarin clearly feels that there is still a real opportunity and is prepared to take on Sarepta and PTC Therapeutics in the competition to hustle ahead new DMD drugs to regulators. ... This month also saw CAR-T “ wunder-kid” Juno Therapeutics

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest appointments

  • Minoryx Therapeutics adds to board of directors Minoryx Therapeutics adds to board of directors

    Dr Claude Nicaise has joined Barcelona, Spain-based Minoryx Therapeutics as an independent board member. ... He brings over 30 years of regulatory strategy expertise to the orphan diseases specialist, and currently also serves as a board member at

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

  • Random42 Scientific Communication

    Boston Biomedical. Boston Scientific . Bristol-Myers Squibb. BTG. Celgene. Ceva. Chiesi. Cidara Therapeutics. ... Procter &Gamble. Reckitt Benckiser. Regeneron. Replicel. Roche. RPS. Sanofi. Santen. Sarepta Therapeutics.

  • Random42 Scientific Communication

    Boston Biomedical. Boston Scientific . Bristol-Myers Squibb. BTG. Celgene. Ceva. Chiesi. Cidara Therapeutics. ... Procter &Gamble. Reckitt Benckiser. Regeneron. Replicel. Roche. RPS. Sanofi. Santen. Sarepta Therapeutics.

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Clark Health Communications

Clark Health Communications (CHC) is an independent, award-winning health and medical communications agency. Our collaboration with experts and advocates enhances...

Latest intelligence

EU
Innovation in merger control and the impact on the pharmaceutical sector
Is focusing on pipeline products enough to assess regulatory risks?...
Nudge-nudge, think-think
Chris Ross examines the personal complexities of human behaviour – and explains why fun, emotion and peer endorsement could be key to designing effective behavioural change programmes...
Peoples Award
Quality in Care Diabetes 2018: the best in innovative diabetes care
Awards highlight new evidence-based approaches to improving care...

Infographics